Antibiotic prophylaxis for transrectal prostate biopsy : In the context of restricted indications for fluoroquinolones and antibiotic stewardship
© 2021. The Author(s)..
BACKGROUND: Transrectal prostate biopsy (TRPB) is the gold standard for prostate cancer diagnosis and among the most common urological interventions. Short-term antibiotic prophylaxis (PAP) is recommended for TRPB. Fluoroquinolone-PAP as standard of care needs to be revaluated due to the restrictions on the use of fluoroquinolone antibiotics by the German Federal Institute for Drugs and Medical Devices.
OBJECTIVES: The aim of the study was to analyze clinical practice of PAP for TRPB with focus on infectious complications and potential differences between fluoroquinolone-PAP and cotrimoxazole-PAP.
METHODS: We performed a retrospective monocentric study of clinical and microbiological characteristics of patients with TRPB between 3 January 2019 and 28 January 2021.
RESULTS: A total of 508 men were included; median age was 68 years. In all, 55.9% of our cohort received cotrimoxazole-PAP and 40.0% fluoroquinolone-PAP. Postinterventional complications occurred in 5.5%, of those 50.0% were infectious complications. Complication rate did not differ between patients with fluoroquinolone-PAP and cotrimoxazole-PAP. Urinary cultures in case of postinterventional complications yielded pathogens with antimicrobial resistance against the used PAP substance indicating selection of resistant bacteria.
CONCLUSION: Cotrimoxazole-PAP for TRPB is not associated with an increase of infectious complications compared to fluoroquinolone-PAP. Cultures obtained prior to TRPB to identify antimicrobial resistance facilitate targeted PAP and therefore can reduce complications.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:61 |
|---|---|
| Enthalten in: |
Der Urologe. Ausg. A - 61(2022), 2 vom: 18. Feb., Seite 160-166 |
| Sprache: |
Deutsch |
|---|
| Weiterer Titel: |
Antibiotikaprophylaxe bei transrektaler Prostatabiopsie : Im Kontext von Fluorchinolon-Indikationsrücknahme und Antibiotic Stewardship |
|---|
| Beteiligte Personen: |
Rothe, Kathrin [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-Bacterial Agents |
|---|
| Anmerkungen: |
Date Completed 14.02.2022 Date Revised 01.06.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00120-021-01618-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM329529803 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM329529803 | ||
| 003 | DE-627 | ||
| 005 | 20231225205319.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||ger c | ||
| 024 | 7 | |a 10.1007/s00120-021-01618-1 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1098.xml |
| 035 | |a (DE-627)NLM329529803 | ||
| 035 | |a (NLM)34409489 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a ger | ||
| 100 | 1 | |a Rothe, Kathrin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Antibiotic prophylaxis for transrectal prostate biopsy |b In the context of restricted indications for fluoroquinolones and antibiotic stewardship |
| 246 | 3 | 3 | |a Antibiotikaprophylaxe bei transrektaler Prostatabiopsie : Im Kontext von Fluorchinolon-Indikationsrücknahme und Antibiotic Stewardship |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.02.2022 | ||
| 500 | |a Date Revised 01.06.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021. The Author(s). | ||
| 520 | |a BACKGROUND: Transrectal prostate biopsy (TRPB) is the gold standard for prostate cancer diagnosis and among the most common urological interventions. Short-term antibiotic prophylaxis (PAP) is recommended for TRPB. Fluoroquinolone-PAP as standard of care needs to be revaluated due to the restrictions on the use of fluoroquinolone antibiotics by the German Federal Institute for Drugs and Medical Devices | ||
| 520 | |a OBJECTIVES: The aim of the study was to analyze clinical practice of PAP for TRPB with focus on infectious complications and potential differences between fluoroquinolone-PAP and cotrimoxazole-PAP | ||
| 520 | |a METHODS: We performed a retrospective monocentric study of clinical and microbiological characteristics of patients with TRPB between 3 January 2019 and 28 January 2021 | ||
| 520 | |a RESULTS: A total of 508 men were included; median age was 68 years. In all, 55.9% of our cohort received cotrimoxazole-PAP and 40.0% fluoroquinolone-PAP. Postinterventional complications occurred in 5.5%, of those 50.0% were infectious complications. Complication rate did not differ between patients with fluoroquinolone-PAP and cotrimoxazole-PAP. Urinary cultures in case of postinterventional complications yielded pathogens with antimicrobial resistance against the used PAP substance indicating selection of resistant bacteria | ||
| 520 | |a CONCLUSION: Cotrimoxazole-PAP for TRPB is not associated with an increase of infectious complications compared to fluoroquinolone-PAP. Cultures obtained prior to TRPB to identify antimicrobial resistance facilitate targeted PAP and therefore can reduce complications | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Antimicrobial resistance | |
| 650 | 4 | |a Clinical practice of PAP | |
| 650 | 4 | |a Fluoroquinolone-PAP | |
| 650 | 4 | |a Infectious complications | |
| 650 | 4 | |a Targeted PAPs | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Fluoroquinolones |2 NLM | |
| 700 | 1 | |a Querbach, Christiane |e verfasserin |4 aut | |
| 700 | 1 | |a Busch, Dirk H |e verfasserin |4 aut | |
| 700 | 1 | |a Gschwend, Jürgen E |e verfasserin |4 aut | |
| 700 | 1 | |a Hauner, Katharina |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Der Urologe. Ausg. A |d 1972 |g 61(2022), 2 vom: 18. Feb., Seite 160-166 |w (DE-627)NLM000215821 |x 1433-0563 |7 nnns |
| 773 | 1 | 8 | |g volume:61 |g year:2022 |g number:2 |g day:18 |g month:02 |g pages:160-166 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00120-021-01618-1 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 61 |j 2022 |e 2 |b 18 |c 02 |h 160-166 | ||